Bordetella Vaccine for Animal and Human Respiratory Disease

Background

Bordetella bronchiseptica causes respiratory diseases in various animals, such as swine, dogs, cats, sheep, guinea pigs, rabbits, mice and rats. Commercially available B. bronchiseptica vaccines (Bordetella vaccines) include live, attenuated, heat-killed, or genetically modified bacteria, all of which are associated with problems such as: persistence of vaccine strain in the host; retention of some of the virulence characteristics; or poor induction of antibody response and protective immunity. The bacterium is also capable of infecting immunocompromised humans, e.g. AIDS and cystic fibrosis patients.

Invention Summary

Inventors in the Microbiology and Immunology Department at Wake Forest School of Medicine have developed an acellular B. bronchiseptica vaccine comprised of the immunogenic BcfA (Bordetella colonization factor A) protein, which with remarkable efficacy establishes protective immunity in vivo against Bordetella infections.

This novel BcfA accellular vaccine can efficiently elicit protective immune responses without the risk of subsequent infection by the vaccine strain and disease, as is the case with the present commercially available vaccines for Bordetella respiratory infections.

Benefits

  • This vaccine does not contain whole-cell bacteria, which eliminates the risk of infection by vaccine strain in the host and subsequent disease or zoonosis.
  • This vaccine is cost-effectively produced by using recombinant DNA techniques.
  • This  vaccine is highly potent and targets multiple animal species of B. bronchiseptica strains.
  • BcfA protein can be incorporated into a multivalent vaccine, which gives prospects of obtaining greater efficacy and broader protection.

Application Fields

  • Vaccines for animal and human respiratory disease
  • Use of serum to prophylactically treat human and animal infections

Status

  • Identified and purified the protein
  • Shown that it is critical for colonization of the mouse trachea
  • Demonstrated that BcfA anti-serum can provide protection in animals and are in the process to show that this anti-sera can provide protection against B. pertussis infections
  • Currently testing whether purified BcfA protein provides protection against B. bronchiseptica and B. pertussis in mouse models
  • It is also planned to test the efficacy of the anti-sera and the purified protein to protect against B. pertussis in nonhuman primates.
  • Patent pending: PCT/US2008/012051

Inventors

Rajendar K. Deora, PhD, Microbiology and Immunology
Meenu Mishra, PhD, Microbiology and Immunology
Neelima Sukumar, PhD, Microbiology and Immunology

Publications

Sukumar N. et al. 2009, Infection and Immunity, 77(2), 885-895
Sukumar et al. 2007, J. Bacteriol. 189:3695-3704

Licensing Contact

Stephen Susalka, PhD
Associate Director, Commercialization
+1.336.716.4029
ssusalka@wakehealth.edu

Back to Top